Gilead Sciences is coming off of a milestone year that saw the start of the much-anticipated launch of the world’s first twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) medicine Ye | ...
Gilead Sciences, after striking a similar deal in 2014 to delay generics of its earlier HIV pre-exposure prophylaxis (PrEP) med Truvada, has followed suit on its key next-gen offering Descovy. Monday, ...
A federal jury Tuesday handed Gilead Sciences Inc. a victory against the U.S. government in a long, contentious battle over control of three patents for two important HIV-fighting drugs. The verdict ...
A federal judge in Texas has ruled that a provision of the Affordable Care Act that mandates free coverage of certain drugs that prevent HIV infections violate the religious beliefs of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results